Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valneva SE

www.valneva.com

Latest From Valneva SE

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

Appointments: ThermiGen, ReForm Biologics, Hookipa Biotech and Faron

This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.

Appointments BioPharmaceutical

Appointments: IRX Therapeutics, Therachon, Mission Therapeutics and bluebird bio

This week’s roundup includes CEO appointments by Smart Matrix and IRX Therapeutics, with various senior level appointments by companies including Therachon, Mission Therapeutics and bluebird bio.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Vivalis
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Valneva SE
  • Senior Management
  • Thomas Lingelbach , Pres. & CEO
    David Lawrence, CFO
    Franck Grimaud, CBO
    Wolfgang Bender, MD, PhD, CMO
  • Contact Info
  • Valneva SE
    Phone: (33) 4 78 76 61 01
    10-12 boulevard Marius Vivier Merle
    Tour Oxygène
    Lyon, 69003
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register